Rinvoq Approved for Active Ankylosing Spondylitis
The approval was based on data from the phase 2/3 SELECT-AXIS 1 and the phase 3 SELECT-AXIS 2 trials.
General Rheumatology
EULAR Recommendations for CV Risk Management in Rheumatic and Musculoskeletal Diseases
A EULAR task force recently developed recommendations for the management of cardiovascular risk in patients with rheumatic and musculoskeletal diseases, including gout, lupus, and systemic sclerosis.
Cosentyx Approved for Enthesitis-Related Arthritis, Juvenile Psoriatic Arthritis
The approval was based on data from the 2-year phase 3 JUNIPERA study that evaluated secukinumab in pediatric patients aged 2 to 17 years with a confirmed diagnosis of ERA or JPsA.
Yusimry, a Humira Biosimilar Product, Gets FDA Approval
The approval was based on a comprehensive data package demonstrating that Yusimry was highly similar to the reference product, Humira.
Significant Improvements Seen With Bimekizumab in Ankylosing Spondylitis Trial
The ongoing phase 3 BE MOBILE 2 study compared the efficacy and safety of bimekizumab to placebo in 332 adults with active ankylosing spondylitis.
Xeljanz/Xeljanz XR Approved for Active Ankylosing Spondylitis
The approval was based on data from a phase 3 study which evaluated tofacitinib in adults with active AS who had an inadequate response to at least 2 NSAIDs.
Tocilizumab Shortage Prompts Temporary REMS Change for CAR T-Cell Therapy
Shortly after an EUA was issued, Genentech announced that tocilizumab (marketed under the brand name Actemra) was in shortage.
Flare Risk Reduced With Secukinumab in 2 Types of Juvenile Idiopathic Arthritis
Findings showed that treatment with secukinumab resulted in a 72% reduction in the risk of flare at week 104 compared with placebo.
FDA Warnings on JAK Inhibitors Show Need for Lifestyle Interventions in Autoimmune Disease Treatment
Nicole Bundy, MD, MPH, discusses the need for lifestyle interventions, in addition to pharmacologic treatment, during the management of patients with autoimmune diseases.
Does Anakinra Have a Role in the Treatment of Severe COVID-19?
Authors of a commentary assessed the role of IL-1 receptor antagonism, specifically anakinra, in the treatment of patients with severe COVID-19.
- Loading...
Loading...
Loading... 
Loading...